Esperion Therapeutics
ESPR
ESPR
166 hedge funds and large institutions have $1.17B invested in Esperion Therapeutics in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 52 increasing their positions, 60 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
29% less capital invested
Capital invested by funds: $1.64B → $1.17B (-$474M)
41% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 27
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
166
Holding in Top 10
2
Calls
$22.9M
Puts
$16.5M
Top Buyers
| 1 | +$43.3M | |
| 2 | +$9.29M | |
| 3 | +$7.52M | |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$6.55M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$6.04M |
Top Sellers
| 1 | -$28.7M | |
| 2 | -$9.91M | |
| 3 | -$7.56M | |
| 4 |
Barclays
London,
United Kingdom
|
-$6.44M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.39M |